Replies to post #210661 on Biotech Values

[DewDiligence]

ABT +2%/PM on 1Q17 results:

http://finance.yahoo.com/news/abbott-reports-first-quarter-2017-114500041.html

1Q17 non-GAAP EPS was $0.48, beating the Street consensus and ABT’s prior guidance of $0.42-0.44. 1Q17 sales grew 30% YoY including the contribution from STJ, and 3% YoY excluding STJ. (The ABT-STJ merger closed on 1/4/17.)

Non-GAAP EPS guidance for 2017 is unchanged at $2.40-2.50.

[DewDiligence]

ALR files what will likely be its last-ever 10-Q:

https://www.sec.gov/Archives/edgar/data/1145460/000119312517203491/d374871d10q.htm

As previously disclosed, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians.

On June 8, 2017 we were informed that the U.S. Department of Justice is closing this investigation without taking any action against the Company…

ABT is acquiring ALR for $51/sh in cash.